Calls For NICE Reforms Intensify After Early Enzalutamide Use Rejected
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K.’s health technology assessment body disappoints patient groups with three draft appraisals for prostate cancer therapies.